Functional and immunological characterization of the simian immunodeficiency virus envelope glycoprotein.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Functional and immunological characterization of the simian immunodeficiency virus envelope glycoprotein.

Diss Abstr Int [B]; 52(7):3517 1992. Unique Identifier : AIDSLINE ICDB/93682468
Planelles V; Univ. of California, Davis

Abstract: Retroviral envelope glycoproteins interact with cell receptors and are targets for antiviral immune responses in infected hosts. SIV(mac) is a T-lymphocytopathic lentivirus which causes an AIDS-like disease in rhesus macaques. The envelope gene of SIV(mac) encodes a precursor glycoprotein (gp160) which is cleaved into an external domain (gp130) and a transmembrane domain (gp32). To investigate the functional and immunological properties of the SIV external envelope glycoprotein, we have used genetically engineered mammalian cells to produce recombinant gp130 (rgp130). The rgp130 has the appropriate mol wt, is glycosylated, and has native conformation as determined by binding to the cell receptor for SIV, the CD4 antigen. Rhesus macaques immunized with purified rgp130 generated high titers of antienvelope antibodies. Antibodies from these macaques were tested for in vitro virus neutralization; very low or undetectable levels of neutralization were observed. In contrast, neutralizing antibodies were readily detected in sera from goats immunized with rgp130. With respect to cell-mediated immunity, proliferative responses to rgp130 were demonstrated in PBMC from macaques immunized with the recombinant glycoprotein as well as in PBMC from SIV-infected animals. To test the potential of rgp130 as a subunit vaccine, rgp130-immunized and control macaques were challenged with a lethal dose of SIV(mac)251. None of these animals resisted challenge. These macaques became positive for virus isolation and antigenemia. Thus, immune responses elicited by rgp130 do not confer protection against experimental infection with SIV. (Full text available from University Microfilms International, Ann Arbor, MI, as Order No. AAD91-37151).

Keywords: Animal Antibodies, Viral/ANALYSIS Antigens, CD4/METABOLISM *Gene Products, env Goats Macaca Neutralization Tests *Retroviridae Proteins, Oncogenic Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/METABOLISM SIV/*IMMUNOLOGY Viral Envelope Proteins/*ANALYSIS/IMMUNOLOGY THESIS
930228
M9320874

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .